# A randomised comparison of ten versus three fractions of radiotherapy for palliation in patients unsuitable for radical radiotherapy or chemotherapy

| Submission date 28/02/2001          | <b>Recruitment status</b><br>No longer recruiting | <ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>     |
|-------------------------------------|---|--|
| <b>Registration date</b> 28/02/2001 | <b>Overall study status</b><br>Completed          | <ul> <li>Statistical analysis plan</li> <li>[X] Results</li> </ul> |
| Last Edited<br>11/09/2007           | <b>Condition category</b><br>Cancer               | [] Individual participant data                                     |

**Plain English summary of protocol** Not provided at time of registration

### **Contact information**

**Type(s)** Scientific

**Contact name** Dr Barbara Uscinska

**Contact details** MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

## Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

**Secondary identifying numbers** BA09

## Study information

#### Scientific Title

#### **Study objectives**

To compare the efficacy and side effects of two palliative radiotherapy schedules in patients with bladder cancer considered unsuitable for radical radiotherapy or chemotherapy.

**Ethics approval required** Old ethics approval format

**Ethics approval(s)** Not provided at time of registration

**Study design** Randomised controlled trial

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Not specified

**Study type(s)** Not Specified

Participant information sheet

Health condition(s) or problem(s) studied Cancer

#### Interventions

Two palliative radiotherapy schedules in patients with bladder cancer considered unsuitable for radical radiotherapy or chemotherapy

Intervention Type Other

**Phase** Not Specified

**Primary outcome measure** Change in bladder and bowel symptoms at three months, quality of life, response, survival.

Secondary outcome measures

Not provided at time of registration

**Overall study start date** 01/11/1992

**Completion date** 01/11/1997

# Eligibility

**Key inclusion criteria** Life expectancy of at least three months, no planned administration of cytotoxic chemotherapy

**Participant type(s)** Patient

Age group Not Specified

**Sex** Not Specified

**Target number of participants** 500

**Key exclusion criteria** Not provided at time of registration

**Date of first enrolment** 01/11/1992

**Date of final enrolment** 01/11/1997

#### Locations

**Countries of recruitment** England

United Kingdom

**Study participating centre MRC Clinical Trials Unit** London United Kingdom NW1 2DA

#### Sponsor information

**Organisation** Medical Research Council (MRC) (UK)

**Sponsor details** 20 Park Crescent London United Kingdom W1B 1AL +44 (0)20 7636 5422 clinical.trial@headoffice.mrc.ac.uk

**Sponsor type** Research council

Website http://www.mrc.ac.uk

# Funder(s)

**Funder type** Research council

**Funder Name** Medical Research Council (UK)

Alternative Name(s) Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type** Government organisation

Funding Body Subtype National government

**Location** United Kingdom

### **Results and Publications**

**Publication and dissemination plan** Not provided at time of registration

#### Intention to publish date

#### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

| Study outputs          |          |              |            |                |                 |
|------------------------|----------|--------------|------------|----------------|-----------------|
| Output type            | Details  | Date created | Date added | Peer reviewed? | Patient-facing? |
| <u>Results article</u> | Results: | 01/05/2000   |            | Yes            | No              |